Evommune, Inc. (EVMN)
6.81
+0.50
(+7.92%)
USD |
NYSE |
Oct 29, 16:00
6.70
-0.11
(-1.62%)
After-Hours: 20:00
Evommune Net Income (Quarterly) : -32.25M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -32.25M |
| March 31, 2026 | -21.67M |
| December 31, 2025 | -28.27M |
| September 30, 2025 | -12.48M |
| June 30, 2025 | -13.56M |
| Date | Value |
|---|---|
| March 31, 2025 | -14.56M |
| September 30, 2024 | -15.92M |
| June 30, 2024 | -27.38M |
| March 31, 2024 | -2.784M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -4.89M |
| Anixa Biosciences, Inc. | -2.625M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 32.25M |
| EPS Diluted (Quarterly) | -0.8924 |
| Enterprise Value | 54.92M |
| Earnings Yield | -41.54% |
| Normalized Earnings Yield | -41.54 |